An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants
- PMID: 36801916
- PMCID: PMC9938693
- DOI: 10.1038/s41467-023-36497-x
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants
Abstract
A pro-inflammatory intestinal microbiome is characteristic of Parkinson's disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The prebiotic bar was provided by BetterBiotics Inc which is co-owned by Drs. Keshavarzian, Hamaker, and Sedghi. A provisional patent is pending for the prebiotic mixture used in the bar (Patent Applicant: Purdue Research Foundation, Inventors: Drs. Hamaker, Cantu-Jungles, Keshavarzian, Application Number: 69548-02, Status: Pending, Patent covers the use of prebiotics to improve health). Drs. Keshavarzian, Hamaker, Sedghi, and Cantu-Jungles were not involved in subject recruitment, subject assessments, or statistical analysis of the data. The remaining authors declare no competing interests.
Figures




Similar articles
-
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD Trial.Genomics Proteomics Bioinformatics. 2022 Apr;20(2):274-287. doi: 10.1016/j.gpb.2021.08.009. Epub 2021 Nov 25. Genomics Proteomics Bioinformatics. 2022. PMID: 34839011 Free PMC article. Clinical Trial.
-
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. Trials. 2021. PMID: 33810796 Free PMC article.
-
Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.World J Gastroenterol. 2019 Oct 28;25(40):6129-6144. doi: 10.3748/wjg.v25.i40.6129. World J Gastroenterol. 2019. PMID: 31686768 Free PMC article. Clinical Trial.
-
Designing future prebiotic fiber to target metabolic syndrome.Nutrition. 2014 May;30(5):497-502. doi: 10.1016/j.nut.2013.08.013. Epub 2013 Oct 2. Nutrition. 2014. PMID: 24262515 Review.
-
Prebiotic peptides, their formation, fermentation in the gut, and health implications.Biotechnol Prog. 2021 May;37(3):e3142. doi: 10.1002/btpr.3142. Epub 2021 Mar 16. Biotechnol Prog. 2021. PMID: 33666376 Review.
Cited by
-
The Role of Diet in Parkinson's Disease.J Parkinsons Dis. 2024;14(s1):S21-S34. doi: 10.3233/JPD-230264. J Parkinsons Dis. 2024. PMID: 38251061 Free PMC article. Review.
-
The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.Life (Basel). 2023 Oct 8;13(10):2023. doi: 10.3390/life13102023. Life (Basel). 2023. PMID: 37895405 Free PMC article. Review.
-
Exploring the gut microbiome-Postoperative Cognitive Dysfunction connection: Mechanisms, clinical implications, and future directions.Brain Behav Immun Health. 2024 Mar 29;38:100763. doi: 10.1016/j.bbih.2024.100763. eCollection 2024 Jul. Brain Behav Immun Health. 2024. PMID: 38682010 Free PMC article. Review.
-
The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson's Disease.Mol Neurobiol. 2024 Nov;61(11):9078-9109. doi: 10.1007/s12035-024-04151-2. Epub 2024 Apr 8. Mol Neurobiol. 2024. PMID: 38587699 Review.
-
The Role of Nutraceuticals and Functional Foods in Mitigating Cellular Senescence and Its Related Aspects: A Key Strategy for Delaying or Preventing Aging and Neurodegenerative Disorders.Nutrients. 2025 May 28;17(11):1837. doi: 10.3390/nu17111837. Nutrients. 2025. PMID: 40507106 Free PMC article. Review.
References
-
- Castillo-Alvarez F, Marzo-Sola ME. Role of the gut microbiota in the development of various neurological diseases. Neurologia. 2019;37:492–498. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical